About us Contacts Drug interactions: 390 212
Drug search by name

Eskalith and Platinol

Determining the interaction of Eskalith and Platinol and the possibility of their joint administration.

Check result:
Eskalith <> Platinol
Relevance: 02.09.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Professional:

Coadministration with cisplatin may transiently decrease the serum concentrations of lithium. The exact mechanism and clinical significance of the interaction is unknown. In one case, a patient stabilized on lithium demonstrated declines in serum lithium level from 1.0 to 0.3 mEq/L and from 0.8 to 0.5 on two separate occasions following IV administration of cisplatin 100 mg/m2. The decreases occurred over a 24- to 36-hour period following cisplatin administration, and lithium level returned to near baseline by 48 hours to 72 hours. During the first 24 hours of cisplatin administration, the patient also received fluids, sodium, and mannitol, which may have contributed to the interaction. In another case, a patient stabilized on lithium demonstrated a transient 64% decrease in serum lithium level during the first of four courses of cisplatin-based chemotherapy (20 mg/m2 IV on days 1-5). However, the effect became less pronounced during successive courses, with 48%, 37%, and 32% decreases reported. This patient also received hydration and sodium during each course. There was no change in clinical response to lithium in either case. In a third case, lithium levels did not change significantly following initial administration of cisplatin 50 mg/m2 but increased during subsequent courses in association with deterioration of the patient's renal function secondary to progressive disease in both kidneys. Dose adjustments of lithium were required.

References
  • Beijnen JH, Bais EM, ten Bokkel Huinink WW "Lithium pharmacokinetics during cisplatin-based chemotherapy: a case report." Cancer Chemother Pharmacol 33 (1994): 523-6
  • Pietruszka LJ, Biermann WA, Vlasses PH "Evaluation of cisplatin-lithium interaction." Drug Intell Clin Pharm 19 (1985): 31-2
  • Beijnen JH, Vlasveld LT, Wanders J, ten Bokkel, Huinink WW, Rodenhuis S "Effect of cisplatin-containing chemotherapy on lithium serum concentrations." Ann Pharmacother 26 (1992): 488-90
Eskalith

Generic Name: lithium

Brand name: Eskalith, Lithobid, Lithonate, Lithotabs, Eskalith-CR

Synonyms: n.a.

Platinol

Generic Name: cisplatin

Brand name: Platinol, Platinol-AQ

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction